Role of Interleukin-6 in Exercise

Not Applicable

Completed

• Conditions: Diabetes Mellitus, Type 2; Obesity
• Interventions: Behavioral: Sport; Drug: Tocilizumab; Drug: Sitagliptin

• Registration Number: NCT01073826
• Lead Sponsor: University of Zurich

Brief Summary

The purpose of the study is to understand the role of interleukin-6 during physical activity in patients with type 2 diabetes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-10-19
• Study Start: 2010-02
• Study First Submitted QC: 2010-02-22
• Study First Posted: 2010-02-23
• Primary Completion: 2015-11
• Study Completion: 2016-06
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-31
• Last Update Posted: 2016-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tocilizumab	Sport	Infusion of Tocilizumab and sport intervention
Sitagliptin	Sport	Intake of Sitagliptin and sport intervention
Placebo	Sport	Intake of placebo and sport intervention
Tocilizumab	Tocilizumab	Infusion of Tocilizumab and sport intervention
Sitagliptin	Sitagliptin	Intake of Sitagliptin and sport intervention

Primary Outcome Measures

Name	Time	Method
Glucagon like peptide- 1 (GLP-1)	Change in GLP-1 secretion compared to baseline

Trial Locations

Locations (1)

University Hospital Zurich; 🇨🇭 Zurich, Switzerland